Arecor appoints ex-IXICO CFO Susan Lowther as its new finance chief

Lowther’s first foray into the pharma and biotech sector was with US giant Monsanto, after which she has gone on to work for smaller industry players such as Novacyt, BioWisdom and, more recently, IXICO

Lowther has been appointed to the board with effect from 4 March

Diabetes drug developer Arecor has appointed Susan Lowther as its new chief financial officer.

Lowther has “significant experience” in the life sciences industry, Arecor said, having previously been the finance boss of AIM-listed IXICO PLC (LON:IXI) until December last year.

She has also been the chief bean counter for French cancer diagnostics specialist Novacyt, RiboTargets and BioWisdom, a data analysis firm which was acquired by Instem PLC (LON:INS) back in 2011.

WATCH: Accor strengthens team with appointment of experienced CFO

Lowther started her career at British Gas before moving on to work for US biotech giant Monsanto.

“I am delighted that Susan is joining the Arecor team,” said chief executive Sarah Howell.

“She brings a depth of financial and business expertise that will help us to deliver our ambitious growth plans.

“Following the completion of our successful capital raise last year we are well positioned to leverage our proprietary formulation platform in the development of our clinical products and in technology partnerships with pharmaceutical or biotechnology companies.”

Lowther added: “This is an exciting time to join Arecor and become part of an innovative and ambitious team.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Instem Plc 'very positive about 2017 clinical opportunites'

Instem Plc (LON:INS) said the performance of its clinical arm had further deteriorated since it last updated and will fall “materially short” of its financial targets. The remainder of the business, which provides analytical software to drug developers, has seen “increased...

on 11/23/2016

2 min read